CEL-SCI Co. (NYSEAMERICAN:CVM) – Equities researchers at Zacks Investment Research reduced their FY2019 earnings per share estimates for CEL-SCI in a note issued to investors on Monday, May 20th. Zacks Investment Research analyst J. Vandermosten now expects that the company will earn ($0.37) per share for the year, down from their previous forecast of ($0.29).

Shares of NYSEAMERICAN CVM opened at $5.02 on Wednesday. CEL-SCI has a 1 year low of $0.82 and a 1 year high of $8.47.

A number of large investors have recently bought and sold shares of CVM. BlackRock Inc. raised its position in shares of CEL-SCI by 370.7% in the third quarter. BlackRock Inc. now owns 603,914 shares of the company’s stock valued at $2,446,000 after buying an additional 475,600 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of CEL-SCI in the first quarter valued at about $629,000. D.A. Davidson & CO. raised its position in shares of CEL-SCI by 115.1% in the fourth quarter. D.A. Davidson & CO. now owns 301,200 shares of the company’s stock valued at $864,000 after buying an additional 161,200 shares during the last quarter. Vanguard Group Inc raised its position in shares of CEL-SCI by 29.7% in the third quarter. Vanguard Group Inc now owns 562,208 shares of the company’s stock valued at $2,277,000 after buying an additional 128,764 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of CEL-SCI by 29.7% in the third quarter. Vanguard Group Inc. now owns 562,208 shares of the company’s stock valued at $2,277,000 after buying an additional 128,764 shares during the last quarter.

About CEL-SCI

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Featured Article: Gross Domestic Product (GDP)

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.